BioVaxys Announces BVX-0320 Poster Presentation at ISIRV-WHO Virtual Conference
BioVaxys Technology Corp. (OTCQB: BVAXF) announced a presentation of preclinical data for its SARS-CoV-2 vaccine candidate, BVX-0320, at the ISIRV-WHO Virtual Congress on October 19-21, 2021. The poster, authored by Chief Medical Officer David Berd, showcases significant antibody and T cell responses in a murine model. The company is advancing its haptenized viral protein technology and preparing for a clinical trial of its cancer vaccine. BioVaxys emphasizes that it does not claim ability to treat SARS-CoV-2 at this time.
- Presentation of BVX-0320 data at the ISIRV-WHO Virtual Congress highlights significant scientific progress.
- Strong antibody and T cell responses observed in murine model indicate potential effectiveness of BVX-0320.
- No current capability to treat SARS-CoV-2, limiting immediate market impact.
- Dependence on successful regulatory approval and clinical trials introduces significant risk.
SARS-Cov-2 spike protein vaccine induced strong antibody and T cell responses in murine model
VANCOUVER, BC, Oct. 8, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that a poster highlighting its preclinical data on BVX-0320, the Company's SARS-CoV-2 vaccine candidate based on its haptenized viral protein technology, will be presented at a joint Virtual Congress of the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) and the World Health Organization (WHO), which is being held October 19-21, 2021.
Details of the poster presentation are as follows:
Title: A Novel Hapten-Modified SARS-CoV-2 Spike Protein Vaccine (BVX-0320) Induces Antibody and T Cell Responses in a Murine Model
Author: David Berd, MD, BioVaxys Technology Corp.
Poster Viewing Times: October 19, 17:35 CET; October 20, 17:30 CET
ISIRV was founded in 2005 as the first independent international scientific society for focused promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases.
"This is the first peer-reviewed presentation of our work on BVX-0320 in mice. We expect it to be well received by the scientific community because it is novel and the data convincing," said David Berd, MD, Chief Medical Officer of BioVaxys.
For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.
About BioVaxys Technology Corp.
Based in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has multiple issued US patents and pending patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
+1 646 452 7054
Cautionary Statements Regarding Forward Looking Information
This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the murine model study, regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys' vaccines, including any haptenized SARS-Cov-2 protein vaccine. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.
These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.
The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Media Contacts BioVaxys Technology Corp.
Gina Cestari, Senior VP
6 Degrees Public Relations
+1 917 797 7904
gcestari@6degreespr.com
View original content:https://www.prnewswire.com/news-releases/biovaxys-announces-bvx-0320-poster-presentation-at-isirv-who-virtual-conference-301395772.html
SOURCE BioVaxys Technology Corp.
FAQ
What vaccine candidate is BioVaxys presenting at the ISIRV-WHO Virtual Congress?
What are the expected presentation dates for BVX-0320 data?
What key findings were reported for BVX-0320?
What is the stock symbol for BioVaxys Technology Corp.?
Is BioVaxys making claims about treating SARS-CoV-2?
